

Table 1. Overview of TEAEs and most common TEAEs (occurring in ≥ 2 patients) in patients with POS by low-dose (4 and 6 mg/day) and high-dose (8, 10, and 12 mg/day) perampanel (Safety Analysis Set)

	Low-dose perampanel (n=73)	High-dose perampanel (n=15)
TEAEs, n (%)	56 (76.7)	9 (60.0)
Most common TEAEs (≥ 2 patients), n (%)		
Dizziness	36 (49.3)	7 (46.7)
Somnolence	8 (11.0)	2 (13.3)
Headache	7 (9.6)	0 (0.0)
Dysarthria	3 (4.1)	1 (6.7)
Edema	2 (2.7)	0 (0.0)
Fatigue	2 (2.7)	0 (0.0)
Pruritus	2 (2.7)	0 (0.0)
Seizure	2 (2.7)	0 (0.0)
Serious TEAEs, n (%)	5 (6.9)	1 (6.7)
TEAEs leading to discontinuation, n (%)	4 (5.5)	0 (0.0)
Dizziness	3 (4.1)	0 (0.0)
Depression	1 (1.4)	0 (0.0)
Suicide attempt	1 (1.4)	0 (0.0)

POS, partial-onset seizures; TEAE, treatment-emergent adverse event